DOES SHORT-TERM ANDROGEN DEPLETION ADD TO HIGH DOSE RADIOTHERAPY (80 GY) IN LOCALIZED INTERMEDIATE RISK PROSTATE CANCER? INTERMEDIARY ANALYSIS OF GETUG 14/0207 RANDOMIZED TRIAL.


1 - CRLCC Jean Bernard, Reims, France; 2 - CRLCC Alfred Vautrin, Nancy, France; 3 - CRLCC Emile Muller, Strasbourg, France; 4 - CRLCC Eugène Marquis, Rennes, France; 5 - CHU Béziers, Béziers, France; 6 - CRLCC Antoine Lacassagne, Nice, France; 7 - CRLCC Jean Godinot, Valence, France; 8 - CHU Saint-Louis, Paris, France; 9 - Clinique Vaudoise, Lausanne, Switzerland; 10 - Hôpital Val-de-Grâce, Paris, France; 11 - CHU Henri Mondor, Créteil, France; 12 - CRLCC Claudius Regaud, Toulouse, France; 13 - CRLCC Val d’Aurelle, Montpellier, France; 14 - Hôpital de Hauteville, Marseille, France; 15 - CRLCC Louis Pradel, Lyon, France; 16 - CHU Poitiers-Saint-Pierre, Poitiers, France; 17 - FRMCC: Federation Nationale des Centres de Lutte Contre le Cancer, Paris, France

A French national multicentric study sponsored by the National Federation of Comprehensive Cancer Centers (FRMCC)

PATIENTS’ CHARACTERISTICS

ANDROGEN DEPRIVATION

BIOCHEMICAL OR CLINICAL CONTROL

3-year survival rate **

URINARY TOXICITIES

3-year cumulative hazard **

GASTRO-INTESTINAL TOXICITIES

3-year cumulative hazard **

CONCLUSIONS

- 377 patients entered between October 2006 and July 2010
- Trial prematurely closed due to slow accrual
- Planned interim analysis with median follow-up of 37.4 months
- The observed difference in favor of Arm 2 (AD-RT) did not reach statistical significance
- The final analysis is scheduled for 2013

ACKNOWLEDGEMENTS

- The patients who have consented to participate in this study
- All participating investigational sites
- The French National Cancer Centre
- The French Health Ministry (INHIC)
- All financial partners

PARTICIPATING CENTERS